24.08.2010A successful entrance into an exclusive licensing agreement with Genentech Inc.You are hereNewsA successful entrance into an exclusive licensing agreement with Genentech Inc.
PLAN-LES-OUATES, Switzerland-(BUSINESS WIRE)
NovImmune, an antibody-focused research and development biotech company, announced today that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.
The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development. Under the terms of the agreement NovImmune will receive an upfront payment and is eligible to receive clinical milestones and royalties on sales. Full financial terms have not been disclosed.
BioAlps World Visibitlity Package 201918.03.2019A yearly international programme for our affiliated companies to increase their visibility.
AptissenMedical technology, DevicesAptissen S.A. is a Swiss company specialized in the development and commercialization of biopolymer-based medical devices. Aptissen’s founders have developed for the past 25 years the best quality injectable products which meet both patients and doctor’s expectations.
Aptissen's team revolutionized the viscosupplement market with Synolis VA and its patented formulation which combines Hyaluronic Acid and Sorbitol. Synolis VA provides rapid mobility recovery, fast long-lasting pain relief associated with excellent safety: www.synolis.com